JP2019517587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517587A5 JP2019517587A5 JP2019516086A JP2019516086A JP2019517587A5 JP 2019517587 A5 JP2019517587 A5 JP 2019517587A5 JP 2019516086 A JP2019516086 A JP 2019516086A JP 2019516086 A JP2019516086 A JP 2019516086A JP 2019517587 A5 JP2019517587 A5 JP 2019517587A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- administered
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125904 compound 1 Drugs 0.000 claims description 39
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 claims description 12
- 229930003316 Vitamin D Natural products 0.000 claims description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 12
- 235000020964 calcitriol Nutrition 0.000 claims description 12
- 239000011612 calcitriol Substances 0.000 claims description 12
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 12
- 229960005084 calcitriol Drugs 0.000 claims description 12
- 239000013589 supplement Substances 0.000 claims description 12
- 235000019166 vitamin D Nutrition 0.000 claims description 12
- 239000011710 vitamin D Substances 0.000 claims description 12
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 12
- 229940046008 vitamin d Drugs 0.000 claims description 12
- 229960005069 calcium Drugs 0.000 claims description 8
- 235000001465 calcium Nutrition 0.000 claims description 8
- 239000012931 lyophilized formulation Substances 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 230000004094 calcium homeostasis Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000009469 supplementation Effects 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 48
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346344P | 2016-06-06 | 2016-06-06 | |
| US62/346,344 | 2016-06-06 | ||
| PCT/US2017/035892 WO2017214014A1 (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517587A JP2019517587A (ja) | 2019-06-24 |
| JP2019517587A5 true JP2019517587A5 (enExample) | 2020-07-30 |
| JP7163281B2 JP7163281B2 (ja) | 2022-10-31 |
Family
ID=60482040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516086A Active JP7163281B2 (ja) | 2016-06-06 | 2017-06-05 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10245258B2 (enExample) |
| EP (1) | EP3463358A4 (enExample) |
| JP (1) | JP7163281B2 (enExample) |
| KR (1) | KR20190015300A (enExample) |
| CN (2) | CN109414436A (enExample) |
| AU (2) | AU2017278114B2 (enExample) |
| BR (1) | BR112018075206A2 (enExample) |
| CA (1) | CA3026396A1 (enExample) |
| CL (1) | CL2018003499A1 (enExample) |
| EA (1) | EA201892746A1 (enExample) |
| IL (1) | IL262565B (enExample) |
| MX (1) | MX388717B (enExample) |
| SG (1) | SG11201809501PA (enExample) |
| WO (1) | WO2017214014A1 (enExample) |
| ZA (1) | ZA201807105B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| WO2017120446A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
| CN118834201A (zh) | 2016-12-01 | 2024-10-25 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| CA3125189A1 (en) * | 2018-12-31 | 2020-07-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| US11583536B2 (en) | 2019-10-21 | 2023-02-21 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| AU2020379680A1 (en) * | 2019-11-05 | 2022-05-26 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide |
| AU2020396543A1 (en) | 2019-12-06 | 2022-06-16 | Celgene Corporation | Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| MX2022011523A (es) * | 2020-03-16 | 2022-12-13 | Celgene Corp | Terapia combinada para leucemia mielógena aguda. |
| KR20230069144A (ko) * | 2020-09-14 | 2023-05-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태 |
| PE20230847A1 (es) | 2020-09-23 | 2023-05-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon |
| KR20240066906A (ko) * | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005260A (es) * | 2001-12-03 | 2005-03-23 | Novacea Inc | Composiciones farmaceuticas que comprenden compuestos activos de vitamina d. |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US20090175869A1 (en) | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| JP2012527424A (ja) | 2009-05-20 | 2012-11-08 | イブリジェニク ソシエテ アノニム | イネカルシトールの新しい治療的使用 |
| BR112014010417A2 (pt) * | 2011-11-01 | 2014-11-18 | Celgene Corp | Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina |
| WO2015082384A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| WO2017120415A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| CN108601777B (zh) | 2016-01-08 | 2021-08-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 |
| BR112018013761A2 (pt) | 2016-01-08 | 2018-12-11 | Celgene Corp | compostos antiproliferativos e suas composições farmacêuticas e usos |
-
2017
- 2017-06-05 JP JP2019516086A patent/JP7163281B2/ja active Active
- 2017-06-05 WO PCT/US2017/035892 patent/WO2017214014A1/en not_active Ceased
- 2017-06-05 AU AU2017278114A patent/AU2017278114B2/en active Active
- 2017-06-05 CN CN201780035323.6A patent/CN109414436A/zh active Pending
- 2017-06-05 CA CA3026396A patent/CA3026396A1/en active Pending
- 2017-06-05 CN CN202211003162.1A patent/CN115282149A/zh active Pending
- 2017-06-05 SG SG11201809501PA patent/SG11201809501PA/en unknown
- 2017-06-05 EP EP17810774.4A patent/EP3463358A4/en not_active Withdrawn
- 2017-06-05 BR BR112018075206-1A patent/BR112018075206A2/pt not_active Application Discontinuation
- 2017-06-05 EA EA201892746A patent/EA201892746A1/ru unknown
- 2017-06-05 KR KR1020187035780A patent/KR20190015300A/ko not_active Ceased
- 2017-06-05 IL IL262565A patent/IL262565B/en unknown
- 2017-06-05 US US15/614,434 patent/US10245258B2/en active Active
- 2017-06-05 MX MX2018015120A patent/MX388717B/es unknown
-
2018
- 2018-10-24 ZA ZA2018/07105A patent/ZA201807105B/en unknown
- 2018-12-06 CL CL2018003499A patent/CL2018003499A1/es unknown
-
2019
- 2019-02-13 US US16/275,234 patent/US20190175573A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,267 patent/US11590117B2/en active Active
-
2023
- 2023-01-25 US US18/101,499 patent/US20230158009A1/en not_active Abandoned
- 2023-04-06 AU AU2023202159A patent/AU2023202159A1/en not_active Abandoned